Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Clindamycin Phosphate Articles

EDQM suspends cert for Chinese APIs

29 April 2009

Perrigo and Cobrek file for generic Evoclin

23 March 2009

Sinclair and York enter UK co-promotion deal

12 January 2009

Arcutis gets FDA appro for Acanya acne gel

1 December 2008

York buys UK's Derms Dev for L17.5 million

15 October 2007

KV and Beijing Med-Pharm in Chinese Clindesse deal

23 July 2007

KV's fiscal 4th-qtr 2007 sales up 39%

11 June 2007

KV's 4th-qtr 2006 net income increases 16%

19 February 2007

China's SFDA revokes 15 GMP certificates

30 October 2006

Connetics buys PediaMed sales org

16 January 2006

KV and Richter Gedeon expand license deal

12 December 2005

KV Pharma's fiscal 2005 sees 7% sales rise

20 June 2005

Ventiv in new partnership with Connetics

25 April 2005

KV reports record revenues for 2004

7 February 2005

KV Pharma licenses two women's products for Mexico

17 January 2005

Connetics' Evoclin available in the USA

20 December 2004

KV Pharma's Clindesse cleared in the USA

13 December 2004

Connetics' Evoclin cleared in USA

1 November 2004

Fougera first to market generic clindamycin lotion

11 February 2002

Pharmacia & Paladin sign Canadian distribution deal

28 January 2002

Watson signs pact with Pharmacia Corp for Cleocin T

15 June 2000

P&U receives FDA OK for Cleocin

17 August 1999

Showing 1-22 of 22 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS